Nilasma Shrestha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nilasma Shrestha has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anil Pokhrel
Lecturer, Department of Nephrology, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication - Hema Chand
Registrar, Department of Nephrology, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication - Laxman Prasad Adhikary
Professor, Department of Nephrology, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication - Prabal K.C.
Medical Officer, Rasuwa District Hospital, Dhunche, Rasuwa, Nepal
1 shared publication - Pradeep Ghimire
Patan Academy of Health Sciences, Lalitpur, Kathmandu, Nepal
1 shared publication - Pravesh Ghimire
Medical Officer, Kathmandu Medical College Teaching Hospital, Sinamangal, Kathmandu, Nepal
1 shared publication
Latest Publications
- Open Access
- 1 March 2023
- Published by Nepal Journals Online (JOL) in Journal of Kathmandu Medical College
- Vol. 12 (1) , 10-16
Effectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients
Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients. Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5. Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05. Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported. Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.
- 1 March 2023
- Published by Nepal Journals Online (JOL) in Journal of Kathmandu Medical College
- Vol. 12 (1) , 10-16
Open AccessEffectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients
Background: Ferric citrate is novel iron-based phosphate-binding drug for management of hyperphosphataemia and iron-deficiency anaemia in chronic kidney disease (CKD) patients. Objectives: To evaluate impact of ferric citrate therapy on reduction of phosphate levels and improvement in haematological parameters in CKD stages 3-5. Methods: This analytical, observational study was conducted at Kathmandu Medical College Teaching Hospital from 2020 July-December after ethical clearance using convenience sampling method. Non-dialysis dependent patients at CKD stages 3-5, having hyperphosphataemia (serum phosphate >=4.6mg/dL) and anaemia (serum haemoglobin <12 gm%, transferrin saturation <=30%, ferritin <=300ng/mL) were administered with 2gm twice daily dose of ferric citrate for 12 weeks and evaluated on outcomes in terms of reduction in serum phosphate levels and improvement in haematological parameters as study endpoints. Data were entered in Microsoft Excel and analysed in SPSS v.25. Significance level was set at p <0.05. Results: Of 84 study participants, majority had CKD stage 4 (46, 54.76%). A significant reduction (p <0.001) in mean serum phosphate levels of 6.21 ± 1.062 mg/dL from baseline to 4.89 ± 1.100 mg/dL in 12-weeks was observed. Patients with CKD stages 3, 4, and 5 had mean reduction of 1.67 (p = 0.005), 1.40 (p <0.001), and 1.04 mg/dL (p = 0.002) of serum Phosphate level respectively. Significant (p <0.001) improvements in hemoglobin level, serum iron, ferritin, total iron binding capacity, and transferrin saturation were reported. Conclusion: Ferric citrate is effective and well-tolerated phosphate-binder to improve hyperphosphataemia and iron deficiency anaemia in non-dialysis CKD stage 3, 4, and 5.